Fenbendazole protocol for Cancer

[Ravenlocke]

Dr William makis MD

NEW ARTICLE: IVERMECTIN and MEBENDAZOLE Testimonial

- 62 year old Maryland woman with Stage 2 Gastric Cancer reports after 3 months - Johns Hopkins Oncologists don't know about their own Mebendazole PATENT!! 🤯 Cancer patients are benefiting!!

#Ivermectin #oncologist #Mebendazole

https://x.com/makismediciner/status/2030709634940510212

[Frankie Pancakes]

We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients — and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: "Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort."

We analyzed a prospective observational cohort of 197 cancer patients, with 122 completing structured follow-up at approximately six months (61.9% response rate). Patients were prescribed a compounded ivermectin-mebendazole protocol by licensed U.S. providers, and outcomes were collected through standardized digital surveys assessing cancer status, adherence, and safety.

Each capsule contained 25 mg ivermectin and 250 mg mebendazole, with dosing individualized by clinicians — most commonly 1-2 capsules per day, though a subset of patients used higher daily dosing or cyclic regimens depending on disease status and tolerance.

Conclusion

This first-ever real-world analysis of a ivermectin-mebendazole protocol in human cancer patients provides a compelling signal that demands serious attention. While these findings should be interpreted appropriately as hypothesis-generating evidence from a real-world clinical evaluation, the magnitude, internal consistency, and broad distribution of the observed effects cannot be ignored. We are not observing marginal changes or isolated responses — we are observing widespread self-reported disease control across a diverse cancer population, a substantial proportion of patients reporting complete disappearance of detectable cancer, and sustained adherence with favorable tolerability over time.

Taken together, these results challenge the long-standing assumption that meaningful cancer responses must come exclusively from high-cost, high-toxicity therapeutic approaches. A signal of this magnitude — approaching 50% regression or no evidence of disease in a real-world population — would typically trigger immediate large-scale clinical investment if it originated from a novel, patent-protected pharmaceutical agent. Instead, these findings involve repurposed, low-cost drugs that have existed for decades, raising a fundamental question: how many clinically meaningful signals have been overlooked, deprioritized, or never pursued because they fall outside the conventional commercial drug development model?

This analysis does not close the case — but it decisively opens it in a way that can no longer be dismissed. The implications are clear. Prospective, randomized controlled trials are urgently needed to validate these findings, define optimal treatment strategies, and determine the full clinical potential of this protocol. Given the strength of the signal observed here, advancing this line of investigation is no longer optional — it is necessary.


https://www.sott.net/article/505613-...-or-Regression